Bigfoot Biomedical said today that it inked a non-exclusive deal with Eli Lilly (NYSE:LLY) to integrate Eli Lilly’s insulin products into Bigfoot’s investigational insulin delivery devices.

The California-based company expects to launch its first two insulin delivery systems – Bigfoot Inject and Bigfoot Loop – in 2020, contingent upon finishing a pivotal trial and landing regulatory approvals.

“Our agreement with Lilly will enable us to bring Bigfoot’s insulin delivery innovations to the millions of people who trust and rely on Lilly’s insulin products,” co-founder & CEO Jeffrey Brewer said in prepared remarks. “We are thrilled to partner with Lilly in our efforts to innovate for people with diabetes and their care teams.”

Bigfoot is developing a closed-loop automated insulin delivery system and a connected insulin pen – both of which the company plans to offer as monthly subscriptions.

In March last year, Bigfoot reported that it raised $55 million in a Series B with help from its partner, Abbott (NYSE:ABT).